Be the first person to write a business review for DENTSPLY International Inc.

Derma Sciences, Inc. is a specialty medical device / pharmaceutical company focused on wound care. As fully integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care, we have full lines of products in the following categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, Specialty Securement and Closure Devices, and First Aid. With two wholly owned and operated manufacturing facilities in Toronto and China, we also offer exceptional contract manufacturing services for OEM or private label products. Our company’s focus is on developing and driving sales of novel advanced wound care products, along with continuing to drive our contract manufacturing business. Regarding advanced wound care, we have built an innovative line of products that has seen quick adoption by clinicians. The line includes our market leading MEDIHONEY® line of Active Leptospermum Honey dressings, BIOGUARD™ Barrier Dressings for prophylactic infection prevention, XTRASORB™ Super Absorbent Polymer Dressings for highly exuding wounds, ALGICELL® Ag for wounds with high bioburden, and TCC-EZ™ — a gold standard total contact casting system for the management of diabetic foot ulcers.With regard to contract manufacturing, through various acquisitions over the past six years, Derma Sciences has built a strong business with broad capabilities. This strength has helped us to accelerate the growth of our private label and contract manufacturing partnerships with some of the largest distributors and wound / skin care products providers in the world. The recent addition of a First Aid line has provided strong growth to our manufacturing business, as well as the ability to take the rest of our line into the retail channel. As we look to the future, our goal is to increase our leadership position in the growing field of wound and skin care, leveraging both our key brands as well as our manufacturing capabilities, while continuing to bring next-generation products and technologies to the market.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. DexCom, Inc. also provides the SEVEN PLUS, which incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function customizable. Its SEVEN PLUS has FDA and CE Mark approvals. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for continuously monitoring blood glucose levels in patients hospitalized for various conditions. It also has development agreement with Insulet Corporation to integrate its continuous glucose monitoring technology into Insulet’s wireless, handheld OmniPod System Personal Diabetes Manager; and a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring technology into Animas insulin pumps. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Electro-Optical Sciences is seeking FDA approval, so that it can begin commercially marketing the point-of-care product to primary care physicians, dermatologists, and plastic surgeons in the US and through partnerships abroad. Electro-Optical Sciences can detect whether that mole is a sign of a more serious medical condition -- melanoma. The company's lead product is a hand-held imaging device called MelaFind, which captures images of suspicious skin lesions, compares them to other malignant and benign lesions stored in a database, and provides information about whether they should be biopsied. MelaFind is in pivotal clinical trials for its ability to detect skin cancer at an early stage.

Encision Inc., a medical device company, engages in the design, development, manufacture, and marketing of surgical instruments primarily in the United States. Encision company's products provide safety to patients undergoing minimally-invasive surgery. It offers a line of Active Electrode Monitoring (AEM) surgical instruments, which prevents stray electrosurgical burns from insulation failure and capacitive coupling. The company's product line includes a range of articulating instruments, such as scissors, graspers, and dissectors; fixed-tip electrodes; and suction-irrigation electrodes. It also provides line of handles used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and markets AEM monitor product line, which is used in conjunction with AEM Instruments. Encision company sells its products primarily to hospitals through its direct and independent sales representatives. Encision Inc. was founded in 1991 and is based in Boulder, Colorado.

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a leading cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA.Endologix is currently marketing its Powerlink® Delivery System an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company's corporate office is located in Irvine, California.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.